Anticoagulation versus placebo for heart failure in sinus rhythm

CONCLUSIONS: Based on the three RCTs, there is no evidence that oral anticoagulant therapy modifies mortality in people with HF in sinus rhythm. The evidence is uncertain if warfarin has any effect on all-cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events. There is no evidence of a difference in the effect of rivaroxaban on all-cause death compared to placebo. It probably reduces the risk of stroke, but probably increases the risk of major bleedings. The available evidence does not support the routine use of anticoagulation in people with HF who remain in sinus rhythm.PMID:34002371 | DOI:10.1002/14651858.CD003336.pub4
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research